Evidence map›Paper›PMID 42639936›Full record

ReviewAdvanced healthcare materials2026

From Cell-Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery.

Clara Baldari, Claudia Leone, Gabriella Leccese, Claudia De Stradis, Alessandra Invidia, Concetta Quintarelli, Biagio De Angelis, Franco Locatelli, Giuseppe Gigli, Gabriele Maiorano and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Clara Baldari *Department of Experimental Medicine, University of Salento, Lecce, Italy.ORCID https://orcid.org/0000-0002-5950-1163
Claudia Leone *Tecnomed Puglia - Tecnopolo Per La Medicina Di Precisione (Biotech Lecce Hub), Lecce, Italy.
Gabriella LecceseDepartment of Experimental Medicine, University of Salento, Lecce, Italy.ORCID https://orcid.org/0000-0003-2058-0009
Claudia De StradisDepartment of Experimental Medicine, University of Salento, Lecce, Italy.
Alessandra InvidiaDepartment of Experimental Medicine, University of Salento, Lecce, Italy.
Concetta QuintarelliDepartment of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
Biagio De AngelisDepartment of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-7938-737X
Franco LocatelliDepartment of Onco-Haematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-7976-3654
Giuseppe GigliDepartment of Experimental Medicine, University of Salento, Lecce, Italy.
Gabriele Maiorano *Institute of Nanotechnology (NANOTEC) - National Research Council (CNR), Lecce, Italy.ORCID https://orcid.org/0000-0003-2205-2293
Ilaria Elena Palamà *Institute of Nanotechnology (NANOTEC) - National Research Council (CNR), Lecce, Italy.ORCID https://orcid.org/0000-0003-4420-0680

Funding

Italian Health Ministry Project "Biotecnologia, Bioinformatica e Sviluppo farmaceutico" per la creazione di un hub delle scienze della vita, piano operativo salute (Piano di Sviluppo e Coesione del Ministero della Salute 2014-2020), Traiettoria 4, Azione 4.1 T4-AN-01MUR PNRR "National Center for Gene Therapy and Drugs based on RNA Technology" CN00000041 CN3 RNAPNC Italian Health Ministry-Hub Life Science-Terapia Avanzata PNC-E3-2022-23683269PNRR Italian Health Ministry PNRR-MR1-2022-12376725PNRR MUR PRIN PNRR 2022- P2022EPK9BTecnopolo per la medicina di precisione″ (TecnoMed Puglia)-Regione Puglia: DGR 2117_21/11/2018
6 · The paper itself

Abstract

Nonviral gene therapy reached unprecedented clinical prominence, with the approval of lipid nanoparticles (LNPs). Yet, their success remains largely confined to a narrow range of applications and tissues, which reflects the inherent functional constraints based on formulation optimization to overcome intrinsically complex physiological barriers. In contrast, biological membranes evolved to integrate immune evasion, targeting, intracellular trafficking, and membrane fusion within a single functional interface. In this review, we provide a mechanistic comparison between membrane-derived vesicles (MDVs) and hybrid biomimetic systems. We critically examine MDVs from different biological sources, highlighting their unique advantages for gene delivery applications. We also focus on hybrid systems, which merge the biological functionality of naturally derived membranes with the design control of synthetic nanovectors to address key limitations such as inefficient cytosolic release, poor targeting specificity, and transfection of hard-to-engineer cells. This review provides a biologically informed roadmap for designing efficient gene delivery vectors, proposing membrane-integrated nanovesicles (NVs) as "living interfaces" for non-viral gene therapy.

Indexed as

Cell MembraneGene Transfer TechniquesNanoparticlesAnimalsGenetic TherapyHumansbiomimetic nanovectorsgene deliveryhybrid vesiclesmembrane‐derived vesiclesnonviral gene therapy

Identifiers

PMID42639936

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.